Company / Accounts Receivable
Glaukos Corp. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$108.6M
FY2025
5-year range
$33.4M / $108.6M
FY2021-FY2025
Trend
+78.8%
vs FY2024
Sector context
#95 of 143
Health Care
What the data says
At $109M, Glaukos Corp.'s accounts receivable ranks #95 of 143 in the Health Care sector. Accounts Receivable has increased for 4 consecutive years, from $33M in FY2021 to $109M in FY2025.
Based on SEC 10-K filings.
$109M in FY2025 with a 5-year CAGR of +24.7%.
Improved from $40M to $109M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +44.4%
- 5-Year CAGR
- +24.7%
- 10-Year CAGR
- -
Sector benchmark
#95 of 143 in Health CareTop 66% of 143This company $108.6M Sector average $1.3B
▼
-91.8% below sector average
Key checks
Key Insights
- Glaukos Corp.'s accounts receivable has grown for 4 consecutive years.
- 5-year CAGR of +24.7%, indicating consistent growth.
- In FY2025, accounts receivable increased 78.8% year-over-year.
- Ranks #95 out of 143 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $108.6M | +78.8% |
| FY2024 | $60.7M | +52.4% |
| FY2023 | $39.9M | +10.5% |
| FY2022 | $36.1M | +7.9% |
| FY2021 | $33.4M | -7.3% |
| FY2020 | $36.1M | -6.1% |
| FY2019 | $38.4M | +105.7% |
| FY2018 | $18.7M | +12.1% |
| FY2017 | $16.7M | +16.4% |
| FY2016 | $14.3M | +89.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026